Polar Capital’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Polar Capital’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-12,000	Closed	-$203K	–	301
2014 Q4	$203K	Sell	12,000 -11,600	-49%	-$169K	﹤0.01%	273
2014 Q3	$317K	Sell	23,600 -1,634	-6%	-$19.5K	0.01%	258
2014 Q2	$321K	Buy	25,234 +7,510	+42%	+$78.2K	0.01%	257
2014 Q1	$211K	Buy	+17,724	New	+$238K	﹤0.01%	262

Other funds holding INFI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Polar Capital's INFI Position: Q1 2015 in Review

Polar Capital sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q1 2015, closing a stake of 12,000 shares — an estimated $203K sold.

Polar Capital first reported a position in INFI in Q1 2014 and held it in 4 quarters. The position peaked at $321K in Q2 2014. 141 funds tracked by Wall St. Rank hold INFI as of Q1 2015.

Polar Capital reported no remaining Infinity Pharmaceuticals, Inc. position as of Q1 2015 after selling out during the quarter.
Polar Capital sold 12,000 Infinity Pharmaceuticals, Inc. shares in Q1 2015, an estimated $203K.
Polar Capital first reported a position in Infinity Pharmaceuticals, Inc. in Q1 2014 and held it in 4 quarters.
Polar Capital's Infinity Pharmaceuticals, Inc. position peaked at $321K in Q2 2014.
141 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q1 2015.

Based on Polar Capital's 13F filing for Q1 2015, filed 15 May 2015.